Clinical trials: Head and Neck Cancer Patients
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy
This study prospectively recruited esophageal squamous-cell carcinoma patients who received nasogastric tube (NG), gastrostomy feeding and oral intake to compare the changes in nutritional status and quality of life during…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Enteral Nutrition
- Trial name
- NCT04199832
- Testing
- Dietary guidance
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma
- Trial name
- NCT03708822
- Testing
- Docetaxel and Cisplatin and Nimotuzumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Unknown Primary Tumors, Oropharynx Cancer
Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck
In current diagnostic work-up of patients with a cancer of unknown primary (CUP), approximately 50% of the primary tumor lesions remains undetected.
- Trial name
- REFLECT (NCT06100081)
- Testing
- Detection of lesions using fluorescence molecular imaging
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Head and Neck Cancer, Lung Cancer
[18F]HX4 PET/CT Imaging for Detection of Hypoxia
The aim of this study is to investigate the radiotracer [18F]HX4 for non-invasive detection of hypoxia in patients with head and neck, or lung cancer.
- Trial name
- OXYPET (NCT02976883)
- Testing
- [18F]HX4 diagnostic PET/CT scan
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Head and Neck Cancer, NSCLC
A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR mutated lung cancer.
- Trial name
- NCT03246854
- Testing
- DBPR112
- Where
- 2 sites in Taiwan
- Volunteers
- 6 people
- Sponsor
- National Health Research Institutes, Taiwan
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Brain Necrosis
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
It is hypothesized that excessive generation of free radicals involves in the pathogenesis of radiation-induced brain necrosis. This study therefore evaluated the effect of free radical scavenger, edaravone, on radiation-induced…
- Trial name
- NCT01865201
- Testing
- Edaravone, Common fundamental management
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Develop and Test the 'Multi-Faced Continuous Exercise Program' in Operable Head and Neck Cancer Patients
Background: Due to the disease location and related treatments in head and neck areas following with concurrent chemoradiation therapy (CCRT), patients might suffer a series of acute distress and limit their physical activities.
- Trial name
- NCT05267353
- Testing
- Exercise intervention program
- Volunteers
- 390 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Neoplasms
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell…
- Trial name
- NCT00402545
- Testing
- Cetuximab, Docetaxel, Cisplatin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer, Gastric Cancer
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054457
- Testing
- capecitabine, docetaxel
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Cancer
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or…
- Trial name
- NCT00281866
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States, Spain
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
This phase I/II trial investigates the best dose and effect of alisertib in combination with pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer. Alisertib may help block the growth of cancer..
- Trial name
- NCT04555837
- Testing
- Alisertib, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal…
- Trial name
- NCT03601975
- Testing
- Gemcitabine/Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in HNSCC With Residual Disease After Radiation
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy).
- Trial name
- NCT02892201
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
- Trial name
- NCT06919666
- Testing
- NT219
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer
Objective: The aim of this study is to characterize the inflammatory response in patients with head and neck cancer. More specifically, the study intend to investigate inflammatory and genetic differences between the primary…
- Trial name
- NCT07131566
- Testing
- Sentinel Node detection and Biopsy
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Lars Olaf Cardell
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.